- Home
- VNO vs RGEN Comparison
VNO vs RGEN Comparison
Compare VNO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- RGEN
- Stock Information
- Founded
- VNO 1946
- RGEN 1981
- Country
- VNO United States
- RGEN United States
- Employees
- VNO N/A
- RGEN N/A
- Industry
- VNO Real Estate Investment Trusts
- RGEN Medical/Dental Instruments
- Sector
- VNO Real Estate
- RGEN Health Care
- Exchange
- VNO Nasdaq
- RGEN Nasdaq
- Market Cap
- VNO 7.0B
- RGEN 8.0B
- IPO Year
- VNO N/A
- RGEN N/A
- Fundamental
- Price
- VNO $39.13
- RGEN $128.04
- Analyst Decision
- VNO Hold
- RGEN Buy
- Analyst Count
- VNO 11
- RGEN 12
- Target Price
- VNO $38.00
- RGEN $172.67
- AVG Volume (30 Days)
- VNO 1.3M
- RGEN 830.2K
- Earning Date
- VNO 05-05-2025
- RGEN 04-29-2025
- Dividend Yield
- VNO 1.90%
- RGEN N/A
- EPS Growth
- VNO 248.25
- RGEN N/A
- EPS
- VNO 0.52
- RGEN N/A
- Revenue
- VNO $1,929,890,000.00
- RGEN $650,429,000.00
- Revenue This Year
- VNO N/A
- RGEN $13.93
- Revenue Next Year
- VNO $5.12
- RGEN $14.35
- P/E Ratio
- VNO $74.18
- RGEN N/A
- Revenue Growth
- VNO 2.98
- RGEN 4.88
- 52 Week Low
- VNO $22.42
- RGEN $102.97
- 52 Week High
- VNO $46.63
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- VNO 59.91
- RGEN 44.98
- Support Level
- VNO $38.45
- RGEN $123.10
- Resistance Level
- VNO $40.73
- RGEN $135.47
- Average True Range (ATR)
- VNO 1.21
- RGEN 6.85
- MACD
- VNO 0.46
- RGEN -0.74
- Stochastic Oscillator
- VNO 77.01
- RGEN 19.54
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.